• Gerardo Santos-López, Paulina Cortés-Hernández, Verónica Vallejo-Ruiz, and Julio Reyes-Leyva.
• Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica de Oriente, Puebla, Mexico.
• Gac Med Mex. 2021 Jan 1; 157 (1): 848984-89.

AbstractThe first cases of COVID-19, caused by the virus called SARS-CoV-2, were recorded in Wuhan, China, in December 2019; however, its transmission ability caused for the infection to be practically present throughout the world six months later. The origin of the virus appears to be zoonotic; it has been proposed that it comes from a bat and that it may have had an intermediate host that led to its introduction in the human population. SARS-CoV-2 is an enveloped virus, with a positive single-stranded RNA genome, and it binds to the angiotensin-converting enzyme, present in susceptible cells, to infect the human respiratory system. Although other coronaviruses have been previously known, they have not had the same impact, and, therefore, research on pharmacological treatments is not sufficiently developed to face the current challenge. Almost since the beginning of the epidemic, several molecules have been proposed for the treatment of infection; however, there is not yet a drug available with sufficient effectiveness for treatment. This review describes SARS-CoV-2 main characteristics, its replicative cycle, its possible origin and some advances in the development of antiviral treatments.Copyright: © 2020 Permanyer.

13 keywords...

hide…